Cerus CERS
NASDAQ CERS
$2.51 -0.03 (-1.18%)
As of: Sep 9, 2026 · 3:59 PM EDT

Cerus (CERS) Gains from Investment Securities (2013 - 2022)

Cerus' (CERS) quarterly Gains from Investment Securities came in at $1.9 million in Q4 2022, up 475.07% year-over-year from $337000.0 in Q4 2021, and up 21433.33% quarter-over-quarter from $9000.0 in Q3 2022.

Analysis

Cerus (CERS) Gains from Investment Securities (2013 - 2022) Analysis & Trends

Cerus has disclosed Gains from Investment Securities across 5 years of filings, most recently posting $1.9 million for Q4 2022.

  • In Q4 2022, Gains from Investment Securities rose 475.07% year-over-year to $1.9 million; the TTM figure through Dec 2022 stood at $2.2 million (up 1575.0% YoY), while the FY2022 annual figure was $2.2 million, up 1575.0% from the prior year.
  • Gains from Investment Securities came in at $1.9 million for Q4 2022 at Cerus, up from $9000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.9 million in Q4 2022 to a low of -$220000.0 in Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 183.04 Bn 177.44 Bn 7.27 Bn
2 Intuitive Surgical 125.02 Bn 119.81 Bn 1.96 Bn
3 Medtronic 117.84 Bn 109.02 Bn 6.34 Bn
4 Stryker 105.50 Bn 102.02 Bn 4.50 Bn
5 Boston Scientific 66.27 Bn 65.73 Bn 3.85 Bn
6 Edwards Lifesciences 49.60 Bn 45.35 Bn 1.35 Bn
7 Alcon 33.70 Bn 32.24 Bn 1.68 Bn
8 Dexcom 32.06 Bn 30.11 Bn 830.00 Mn
9 Steris 21.02 Bn 20.54 Bn 684.20 Mn
10 Cerus 504.42 Mn 448.16 Mn 29.53 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 1.94 Mn
Sep 30, 2022 9,000.00
Jun 30, 2022 -45,000.00
Mar 31, 2022 281,000.00
Dec 31, 2021 337,000.00
Sep 30, 2021 -83,000.00
Jun 30, 2021 -182,000.00
Mar 31, 2021 -220,000.00
Dec 31, 2015 1.13 Mn
Sep 30, 2015 -1.11 Mn
Jun 30, 2015 2.71 Mn
Mar 31, 2015 -6.30 Mn
Dec 31, 2014 6.56 Mn
Sep 30, 2014 -1.74 Mn
Jun 30, 2014 -3.49 Mn
Mar 31, 2014 -9.03 Mn
Dec 31, 2013 -1.70 Mn
Sep 30, 2013 12.42 Mn